Company intelligence / Profile preview

GuardRX

Ownership: Private
Development stage: Other

Overview

GuardRX is a non-profit developer and coordinator of prophylactic and therapeutic products for neglected and emerging infectious diseases, providing preclinical and clinical development, regulatory support, and cGMP material production. It serves as coordinating organization for clinical trials such as a Phase 1b heterologous booster trial of INO-4201, a DNA Ebola vaccine booster, and supports development of drugs and vaccines for diseases where traditional commercial incentives are lacking.[3][4][5]

Therapeutic areas: Infectious Diseases
Modalities: VaccineSmall moleculeBiologicDNA vaccine
Industry: Drug Discovery Services

Partnerships

InovioGeneva University HospitalsUniversity of Texas Medical Branch (Galveston National Laboratory)DARPA

Beyond the preview

Go deeper on GuardRX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GuardRX.

Explore the full profile